IBDEI06A ; ; 01-AUG-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,15233,1,3,0)
;;=3^Rheumatic Tricuspid Insufficiency
;;^UTILITY(U,$J,358.3,15233,1,4,0)
;;=4^I07.1
;;^UTILITY(U,$J,358.3,15233,2)
;;=^5007048
;;^UTILITY(U,$J,358.3,15234,0)
;;=I07.9^^56^643^22
;;^UTILITY(U,$J,358.3,15234,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15234,1,3,0)
;;=3^Rheumatic Tricuspid Valve Disease,Unspec
;;^UTILITY(U,$J,358.3,15234,1,4,0)
;;=4^I07.9
;;^UTILITY(U,$J,358.3,15234,2)
;;=^5007051
;;^UTILITY(U,$J,358.3,15235,0)
;;=I08.0^^56^643^16
;;^UTILITY(U,$J,358.3,15235,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15235,1,3,0)
;;=3^Rheumatic Disorders of Mitral & Aortic Valves
;;^UTILITY(U,$J,358.3,15235,1,4,0)
;;=4^I08.0
;;^UTILITY(U,$J,358.3,15235,2)
;;=^5007052
;;^UTILITY(U,$J,358.3,15236,0)
;;=I09.89^^56^643^17
;;^UTILITY(U,$J,358.3,15236,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15236,1,3,0)
;;=3^Rheumatic Heart Diseases NEC
;;^UTILITY(U,$J,358.3,15236,1,4,0)
;;=4^I09.89
;;^UTILITY(U,$J,358.3,15236,2)
;;=^5007060
;;^UTILITY(U,$J,358.3,15237,0)
;;=I47.1^^56^643^24
;;^UTILITY(U,$J,358.3,15237,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15237,1,3,0)
;;=3^Supraventricular Tachycardia
;;^UTILITY(U,$J,358.3,15237,1,4,0)
;;=4^I47.1
;;^UTILITY(U,$J,358.3,15237,2)
;;=^5007223
;;^UTILITY(U,$J,358.3,15238,0)
;;=I48.0^^56^643^15
;;^UTILITY(U,$J,358.3,15238,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15238,1,3,0)
;;=3^Paroxysmal Atrial Fibrillation
;;^UTILITY(U,$J,358.3,15238,1,4,0)
;;=4^I48.0
;;^UTILITY(U,$J,358.3,15238,2)
;;=^90473
;;^UTILITY(U,$J,358.3,15239,0)
;;=I49.5^^56^643^23
;;^UTILITY(U,$J,358.3,15239,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15239,1,3,0)
;;=3^Sick Sinus Syndrome
;;^UTILITY(U,$J,358.3,15239,1,4,0)
;;=4^I49.5
;;^UTILITY(U,$J,358.3,15239,2)
;;=^110404
;;^UTILITY(U,$J,358.3,15240,0)
;;=I49.8^^56^643^3
;;^UTILITY(U,$J,358.3,15240,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15240,1,3,0)
;;=3^Cardiac Arrhythmias
;;^UTILITY(U,$J,358.3,15240,1,4,0)
;;=4^I49.8
;;^UTILITY(U,$J,358.3,15240,2)
;;=^5007236
;;^UTILITY(U,$J,358.3,15241,0)
;;=I49.9^^56^643^2
;;^UTILITY(U,$J,358.3,15241,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15241,1,3,0)
;;=3^Cardiac Arrhythmia,Unspec
;;^UTILITY(U,$J,358.3,15241,1,4,0)
;;=4^I49.9
;;^UTILITY(U,$J,358.3,15241,2)
;;=^5007237
;;^UTILITY(U,$J,358.3,15242,0)
;;=R00.1^^56^643^1
;;^UTILITY(U,$J,358.3,15242,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15242,1,3,0)
;;=3^Bradycardia,Unspec
;;^UTILITY(U,$J,358.3,15242,1,4,0)
;;=4^R00.1
;;^UTILITY(U,$J,358.3,15242,2)
;;=^5019164
;;^UTILITY(U,$J,358.3,15243,0)
;;=I34.1^^56^643^14
;;^UTILITY(U,$J,358.3,15243,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15243,1,3,0)
;;=3^Nonrheumatic Mitral Valve Prolapse
;;^UTILITY(U,$J,358.3,15243,1,4,0)
;;=4^I34.1
;;^UTILITY(U,$J,358.3,15243,2)
;;=^5007170
;;^UTILITY(U,$J,358.3,15244,0)
;;=D68.4^^56^644^1
;;^UTILITY(U,$J,358.3,15244,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15244,1,3,0)
;;=3^Acquired Coagulation Factor Deficiency
;;^UTILITY(U,$J,358.3,15244,1,4,0)
;;=4^D68.4
;;^UTILITY(U,$J,358.3,15244,2)
;;=^2235
;;^UTILITY(U,$J,358.3,15245,0)
;;=D59.9^^56^644^2
;;^UTILITY(U,$J,358.3,15245,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15245,1,3,0)
;;=3^Acquired Hemolytic Anemia,Unspec
;;^UTILITY(U,$J,358.3,15245,1,4,0)
;;=4^D59.9
;;^UTILITY(U,$J,358.3,15245,2)
;;=^5002330
;;^UTILITY(U,$J,358.3,15246,0)
;;=C91.00^^56^644^5
;;^UTILITY(U,$J,358.3,15246,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15246,1,3,0)
;;=3^Acute Lymphoblastic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,15246,1,4,0)
;;=4^C91.00
;;^UTILITY(U,$J,358.3,15246,2)
;;=^5001762
;;^UTILITY(U,$J,358.3,15247,0)
;;=C91.01^^56^644^4
;;^UTILITY(U,$J,358.3,15247,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15247,1,3,0)
;;=3^Acute Lymphoblastic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,15247,1,4,0)
;;=4^C91.01
;;^UTILITY(U,$J,358.3,15247,2)
;;=^5001763
;;^UTILITY(U,$J,358.3,15248,0)
;;=C92.01^^56^644^7
;;^UTILITY(U,$J,358.3,15248,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15248,1,3,0)
;;=3^Acute Myeloblastic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,15248,1,4,0)
;;=4^C92.01
;;^UTILITY(U,$J,358.3,15248,2)
;;=^5001790
;;^UTILITY(U,$J,358.3,15249,0)
;;=C92.00^^56^644^8
;;^UTILITY(U,$J,358.3,15249,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15249,1,3,0)
;;=3^Acute Myeloblastic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,15249,1,4,0)
;;=4^C92.00
;;^UTILITY(U,$J,358.3,15249,2)
;;=^5001789
;;^UTILITY(U,$J,358.3,15250,0)
;;=C92.61^^56^644^9
;;^UTILITY(U,$J,358.3,15250,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15250,1,3,0)
;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,In Remission
;;^UTILITY(U,$J,358.3,15250,1,4,0)
;;=4^C92.61
;;^UTILITY(U,$J,358.3,15250,2)
;;=^5001808
;;^UTILITY(U,$J,358.3,15251,0)
;;=C92.60^^56^644^10
;;^UTILITY(U,$J,358.3,15251,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15251,1,3,0)
;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
;;^UTILITY(U,$J,358.3,15251,1,4,0)
;;=4^C92.60
;;^UTILITY(U,$J,358.3,15251,2)
;;=^5001807
;;^UTILITY(U,$J,358.3,15252,0)
;;=C92.A1^^56^644^11
;;^UTILITY(U,$J,358.3,15252,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15252,1,3,0)
;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
;;^UTILITY(U,$J,358.3,15252,1,4,0)
;;=4^C92.A1
;;^UTILITY(U,$J,358.3,15252,2)
;;=^5001814
;;^UTILITY(U,$J,358.3,15253,0)
;;=C92.A0^^56^644^12
;;^UTILITY(U,$J,358.3,15253,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15253,1,3,0)
;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
;;^UTILITY(U,$J,358.3,15253,1,4,0)
;;=4^C92.A0
;;^UTILITY(U,$J,358.3,15253,2)
;;=^5001813
;;^UTILITY(U,$J,358.3,15254,0)
;;=C92.51^^56^644^13
;;^UTILITY(U,$J,358.3,15254,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15254,1,3,0)
;;=3^Acute Myelomonocytic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,15254,1,4,0)
;;=4^C92.51
;;^UTILITY(U,$J,358.3,15254,2)
;;=^5001805
;;^UTILITY(U,$J,358.3,15255,0)
;;=C92.50^^56^644^14
;;^UTILITY(U,$J,358.3,15255,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15255,1,3,0)
;;=3^Acute Myelomonocytic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,15255,1,4,0)
;;=4^C92.50
;;^UTILITY(U,$J,358.3,15255,2)
;;=^5001804
;;^UTILITY(U,$J,358.3,15256,0)
;;=C94.40^^56^644^17
;;^UTILITY(U,$J,358.3,15256,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15256,1,3,0)
;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
;;^UTILITY(U,$J,358.3,15256,1,4,0)
;;=4^C94.40
;;^UTILITY(U,$J,358.3,15256,2)
;;=^5001843
;;^UTILITY(U,$J,358.3,15257,0)
;;=C94.42^^56^644^15
;;^UTILITY(U,$J,358.3,15257,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15257,1,3,0)
;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
;;^UTILITY(U,$J,358.3,15257,1,4,0)
;;=4^C94.42
;;^UTILITY(U,$J,358.3,15257,2)
;;=^5001845
;;^UTILITY(U,$J,358.3,15258,0)
;;=C94.41^^56^644^16
;;^UTILITY(U,$J,358.3,15258,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15258,1,3,0)
;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
;;^UTILITY(U,$J,358.3,15258,1,4,0)
;;=4^C94.41
;;^UTILITY(U,$J,358.3,15258,2)
;;=^5001844
;;^UTILITY(U,$J,358.3,15259,0)
;;=D62.^^56^644^18
;;^UTILITY(U,$J,358.3,15259,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15259,1,3,0)
;;=3^Acute Posthemorrhagic Anemia
;;^UTILITY(U,$J,358.3,15259,1,4,0)
;;=4^D62.
;;^UTILITY(U,$J,358.3,15259,2)
;;=^267986
;;^UTILITY(U,$J,358.3,15260,0)
;;=C92.41^^56^644^19
;;^UTILITY(U,$J,358.3,15260,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15260,1,3,0)
;;=3^Acute Promyelocytic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,15260,1,4,0)
;;=4^C92.41
;;^UTILITY(U,$J,358.3,15260,2)
;;=^5001802
;;^UTILITY(U,$J,358.3,15261,0)
;;=C92.40^^56^644^20
;;^UTILITY(U,$J,358.3,15261,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15261,1,3,0)
;;=3^Acute Promyelocytic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,15261,1,4,0)
;;=4^C92.40
;;^UTILITY(U,$J,358.3,15261,2)
;;=^5001801
;;^UTILITY(U,$J,358.3,15262,0)
;;=D56.0^^56^644^21
;;^UTILITY(U,$J,358.3,15262,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15262,1,3,0)
;;=3^Alpha Thalassemia
;;^UTILITY(U,$J,358.3,15262,1,4,0)
;;=4^D56.0
;;^UTILITY(U,$J,358.3,15262,2)
;;=^340494
;;^UTILITY(U,$J,358.3,15263,0)
;;=D63.1^^56^644^23
;;^UTILITY(U,$J,358.3,15263,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15263,1,3,0)
;;=3^Anemia in Chronic Kidney Disease
;;^UTILITY(U,$J,358.3,15263,1,4,0)
;;=4^D63.1
;;^UTILITY(U,$J,358.3,15263,2)
;;=^332908
;;^UTILITY(U,$J,358.3,15264,0)
;;=D63.0^^56^644^24
;;^UTILITY(U,$J,358.3,15264,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15264,1,3,0)
;;=3^Anemia in Neoplastic Disease
;;^UTILITY(U,$J,358.3,15264,1,4,0)
;;=4^D63.0
;;^UTILITY(U,$J,358.3,15264,2)
;;=^321978
;;^UTILITY(U,$J,358.3,15265,0)
;;=D63.8^^56^644^22
;;^UTILITY(U,$J,358.3,15265,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15265,1,3,0)
;;=3^Anemia in Chronic Diseases Classified Elsewhere
;;^UTILITY(U,$J,358.3,15265,1,4,0)
;;=4^D63.8
;;^UTILITY(U,$J,358.3,15265,2)
;;=^5002343
;;^UTILITY(U,$J,358.3,15266,0)
;;=C22.3^^56^644^27
;;^UTILITY(U,$J,358.3,15266,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15266,1,3,0)
;;=3^Angiosarcoma of Liver
;;^UTILITY(U,$J,358.3,15266,1,4,0)
;;=4^C22.3
;;^UTILITY(U,$J,358.3,15266,2)
;;=^5000936
;;^UTILITY(U,$J,358.3,15267,0)
;;=D61.9^^56^644^28
;;^UTILITY(U,$J,358.3,15267,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15267,1,3,0)
;;=3^Aplastic Anemia,Unspec
;;^UTILITY(U,$J,358.3,15267,1,4,0)
;;=4^D61.9
;;^UTILITY(U,$J,358.3,15267,2)
;;=^5002342
;;^UTILITY(U,$J,358.3,15268,0)
;;=D56.1^^56^644^34
;;^UTILITY(U,$J,358.3,15268,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15268,1,3,0)
;;=3^Beta Thalassemia
;;^UTILITY(U,$J,358.3,15268,1,4,0)
;;=4^D56.1
;;^UTILITY(U,$J,358.3,15268,2)
;;=^340495
;;^UTILITY(U,$J,358.3,15269,0)
;;=C83.79^^56^644^36
;;^UTILITY(U,$J,358.3,15269,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15269,1,3,0)
;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,15269,1,4,0)
;;=4^C83.79
;;^UTILITY(U,$J,358.3,15269,2)
;;=^5001600
;;^UTILITY(U,$J,358.3,15270,0)
;;=C83.70^^56^644^37
;;^UTILITY(U,$J,358.3,15270,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15270,1,3,0)
;;=3^Burkitt Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,15270,1,4,0)
;;=4^C83.70
;;^UTILITY(U,$J,358.3,15270,2)
;;=^5001591
;;^UTILITY(U,$J,358.3,15271,0)
;;=D09.0^^56^644^44
;;^UTILITY(U,$J,358.3,15271,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15271,1,3,0)
;;=3^Carcinoma in Situ of Bladder
;;^UTILITY(U,$J,358.3,15271,1,4,0)
;;=4^D09.0
;;^UTILITY(U,$J,358.3,15271,2)
;;=^267742
;;^UTILITY(U,$J,358.3,15272,0)
;;=D06.9^^56^644^45
;;^UTILITY(U,$J,358.3,15272,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15272,1,3,0)
;;=3^Carcinoma in Situ of Cervix
;;^UTILITY(U,$J,358.3,15272,1,4,0)
;;=4^D06.9
;;^UTILITY(U,$J,358.3,15272,2)
;;=^5001941
;;^UTILITY(U,$J,358.3,15273,0)
;;=D06.0^^56^644^47
;;^UTILITY(U,$J,358.3,15273,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15273,1,3,0)
;;=3^Carcinoma in Situ of Endocervix
;;^UTILITY(U,$J,358.3,15273,1,4,0)
;;=4^D06.0
;;^UTILITY(U,$J,358.3,15273,2)
;;=^5001938
;;^UTILITY(U,$J,358.3,15274,0)
;;=D06.1^^56^644^48
;;^UTILITY(U,$J,358.3,15274,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15274,1,3,0)
;;=3^Carcinoma in Situ of Exocervix
;;^UTILITY(U,$J,358.3,15274,1,4,0)
;;=4^D06.1
;;^UTILITY(U,$J,358.3,15274,2)
;;=^5001939
;;^UTILITY(U,$J,358.3,15275,0)
;;=D06.7^^56^644^46
;;^UTILITY(U,$J,358.3,15275,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15275,1,3,0)
;;=3^Carcinoma in Situ of Cervix,Other Parts
;;^UTILITY(U,$J,358.3,15275,1,4,0)
;;=4^D06.7
;;^UTILITY(U,$J,358.3,15275,2)
;;=^5001940
;;^UTILITY(U,$J,358.3,15276,0)
;;=D04.9^^56^644^49
;;^UTILITY(U,$J,358.3,15276,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15276,1,3,0)
;;=3^Carcinoma in Situ of Skin
;;^UTILITY(U,$J,358.3,15276,1,4,0)
;;=4^D04.9
;;^UTILITY(U,$J,358.3,15276,2)
;;=^5001925
;;^UTILITY(U,$J,358.3,15277,0)
;;=C91.11^^56^644^52
;;^UTILITY(U,$J,358.3,15277,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15277,1,3,0)
;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
;;^UTILITY(U,$J,358.3,15277,1,4,0)
;;=4^C91.11
;;^UTILITY(U,$J,358.3,15277,2)
;;=^5001766
;;^UTILITY(U,$J,358.3,15278,0)
;;=C91.10^^56^644^53
;;^UTILITY(U,$J,358.3,15278,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15278,1,3,0)
;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
;;^UTILITY(U,$J,358.3,15278,1,4,0)
;;=4^C91.10
;;^UTILITY(U,$J,358.3,15278,2)
;;=^5001765
;;^UTILITY(U,$J,358.3,15279,0)
;;=C92.11^^56^644^54
;;^UTILITY(U,$J,358.3,15279,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15279,1,3,0)
;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
;;^UTILITY(U,$J,358.3,15279,1,4,0)
;;=4^C92.11
;;^UTILITY(U,$J,358.3,15279,2)
;;=^5001793
;;^UTILITY(U,$J,358.3,15280,0)
;;=C92.10^^56^644^55
;;^UTILITY(U,$J,358.3,15280,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15280,1,3,0)
;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
;;^UTILITY(U,$J,358.3,15280,1,4,0)
;;=4^C92.10
;;^UTILITY(U,$J,358.3,15280,2)
;;=^5001792
;;^UTILITY(U,$J,358.3,15281,0)
;;=D47.1^^56^644^56
;;^UTILITY(U,$J,358.3,15281,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15281,1,3,0)
;;=3^Chronic Myeloproliferative Disease
;;^UTILITY(U,$J,358.3,15281,1,4,0)
;;=4^D47.1
;;^UTILITY(U,$J,358.3,15281,2)
;;=^5002256
;;^UTILITY(U,$J,358.3,15282,0)
;;=C82.69^^56^644^57
;;^UTILITY(U,$J,358.3,15282,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15282,1,3,0)
;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,15282,1,4,0)
;;=4^C82.69
;;^UTILITY(U,$J,358.3,15282,2)
;;=^5001530
;;^UTILITY(U,$J,358.3,15283,0)
;;=C82.60^^56^644^58
;;^UTILITY(U,$J,358.3,15283,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15283,1,3,0)
;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,15283,1,4,0)
;;=4^C82.60
;;^UTILITY(U,$J,358.3,15283,2)
;;=^5001521
;;^UTILITY(U,$J,358.3,15284,0)
;;=D56.2^^56^644^59
;;^UTILITY(U,$J,358.3,15284,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15284,1,3,0)
;;=3^Delta-Beta Thalassemia
;;^UTILITY(U,$J,358.3,15284,1,4,0)
;;=4^D56.2
;;^UTILITY(U,$J,358.3,15284,2)
;;=^340496
;;^UTILITY(U,$J,358.3,15285,0)
;;=D75.9^^56^644^60
;;^UTILITY(U,$J,358.3,15285,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15285,1,3,0)
;;=3^Disease of Blood/Blood-Forming Organs,Unspec
;;^UTILITY(U,$J,358.3,15285,1,4,0)
;;=4^D75.9
;;^UTILITY(U,$J,358.3,15285,2)
;;=^5002393
;;^UTILITY(U,$J,358.3,15286,0)
;;=D59.0^^56^644^63
;;^UTILITY(U,$J,358.3,15286,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15286,1,3,0)
;;=3^Drug-Induced Autoimmune Hemolytic Anemia
;;^UTILITY(U,$J,358.3,15286,1,4,0)
;;=4^D59.0
;;^UTILITY(U,$J,358.3,15286,2)
;;=^5002323
;;^UTILITY(U,$J,358.3,15287,0)
;;=D59.2^^56^644^64
;;^UTILITY(U,$J,358.3,15287,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15287,1,3,0)
;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
;;^UTILITY(U,$J,358.3,15287,1,4,0)
;;=4^D59.2
;;^UTILITY(U,$J,358.3,15287,2)
;;=^5002325
;;^UTILITY(U,$J,358.3,15288,0)
;;=R59.9^^56^644^67
;;^UTILITY(U,$J,358.3,15288,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15288,1,3,0)
;;=3^Enlarged Lymph Nodes,Unspec
;;^UTILITY(U,$J,358.3,15288,1,4,0)
;;=4^R59.9
;;^UTILITY(U,$J,358.3,15288,2)
;;=^5019531
;;^UTILITY(U,$J,358.3,15289,0)
;;=D47.3^^56^644^68
;;^UTILITY(U,$J,358.3,15289,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15289,1,3,0)
;;=3^Essential Thrombocythemia
;;^UTILITY(U,$J,358.3,15289,1,4,0)
;;=4^D47.3
;;^UTILITY(U,$J,358.3,15289,2)
;;=^5002258
;;^UTILITY(U,$J,358.3,15290,0)
;;=C82.09^^56^644^69
;;^UTILITY(U,$J,358.3,15290,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15290,1,3,0)
;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,15290,1,4,0)
;;=4^C82.09
;;^UTILITY(U,$J,358.3,15290,2)
;;=^5001470
;;^UTILITY(U,$J,358.3,15291,0)
;;=C82.00^^56^644^70
;;^UTILITY(U,$J,358.3,15291,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15291,1,3,0)
;;=3^Follicular Lymphoma Grade I,Unspec Site
;;^UTILITY(U,$J,358.3,15291,1,4,0)
;;=4^C82.00
;;^UTILITY(U,$J,358.3,15291,2)
;;=^5001461
;;^UTILITY(U,$J,358.3,15292,0)
;;=C82.19^^56^644^71
;;^UTILITY(U,$J,358.3,15292,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15292,1,3,0)
;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,15292,1,4,0)
;;=4^C82.19
;;^UTILITY(U,$J,358.3,15292,2)
;;=^5001480
;;^UTILITY(U,$J,358.3,15293,0)
;;=C82.10^^56^644^72
;;^UTILITY(U,$J,358.3,15293,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15293,1,3,0)
;;=3^Follicular Lymphoma Grade II,Unspec Site
;;^UTILITY(U,$J,358.3,15293,1,4,0)
;;=4^C82.10
;;^UTILITY(U,$J,358.3,15293,2)
;;=^5001471
;;^UTILITY(U,$J,358.3,15294,0)
;;=C82.29^^56^644^73
;;^UTILITY(U,$J,358.3,15294,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15294,1,3,0)
;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,15294,1,4,0)
;;=4^C82.29
;;^UTILITY(U,$J,358.3,15294,2)
;;=^5001490
;;^UTILITY(U,$J,358.3,15295,0)
;;=C82.20^^56^644^74
;;^UTILITY(U,$J,358.3,15295,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15295,1,3,0)
;;=3^Follicular Lymphoma Grade III,Unspec Site
;;^UTILITY(U,$J,358.3,15295,1,4,0)
;;=4^C82.20
;;^UTILITY(U,$J,358.3,15295,2)
;;=^5001481
;;^UTILITY(U,$J,358.3,15296,0)
;;=C82.39^^56^644^75
;;^UTILITY(U,$J,358.3,15296,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15296,1,3,0)
;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,15296,1,4,0)
;;=4^C82.39
;;^UTILITY(U,$J,358.3,15296,2)
;;=^5001500
;;^UTILITY(U,$J,358.3,15297,0)
;;=C82.30^^56^644^76
;;^UTILITY(U,$J,358.3,15297,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15297,1,3,0)
;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
;;^UTILITY(U,$J,358.3,15297,1,4,0)
;;=4^C82.30
;;^UTILITY(U,$J,358.3,15297,2)
;;=^5001491
;;^UTILITY(U,$J,358.3,15298,0)
;;=C82.49^^56^644^77
;;^UTILITY(U,$J,358.3,15298,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15298,1,3,0)
;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,15298,1,4,0)
;;=4^C82.49
;;^UTILITY(U,$J,358.3,15298,2)
;;=^5001510
;;^UTILITY(U,$J,358.3,15299,0)
;;=C82.40^^56^644^78
;;^UTILITY(U,$J,358.3,15299,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15299,1,3,0)
;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
;;^UTILITY(U,$J,358.3,15299,1,4,0)
;;=4^C82.40
;;^UTILITY(U,$J,358.3,15299,2)
;;=^5001501
;;^UTILITY(U,$J,358.3,15300,0)
;;=C82.99^^56^644^79
;;^UTILITY(U,$J,358.3,15300,1,0)
;;=^358.31IA^4^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI06A 19756 printed Nov 22, 2024@16:52:41 Page 2
IBDEI06A ; ; 01-AUG-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,15233,1,3,0)
+2 ;;=3^Rheumatic Tricuspid Insufficiency
+3 ;;^UTILITY(U,$J,358.3,15233,1,4,0)
+4 ;;=4^I07.1
+5 ;;^UTILITY(U,$J,358.3,15233,2)
+6 ;;=^5007048
+7 ;;^UTILITY(U,$J,358.3,15234,0)
+8 ;;=I07.9^^56^643^22
+9 ;;^UTILITY(U,$J,358.3,15234,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,15234,1,3,0)
+12 ;;=3^Rheumatic Tricuspid Valve Disease,Unspec
+13 ;;^UTILITY(U,$J,358.3,15234,1,4,0)
+14 ;;=4^I07.9
+15 ;;^UTILITY(U,$J,358.3,15234,2)
+16 ;;=^5007051
+17 ;;^UTILITY(U,$J,358.3,15235,0)
+18 ;;=I08.0^^56^643^16
+19 ;;^UTILITY(U,$J,358.3,15235,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,15235,1,3,0)
+22 ;;=3^Rheumatic Disorders of Mitral & Aortic Valves
+23 ;;^UTILITY(U,$J,358.3,15235,1,4,0)
+24 ;;=4^I08.0
+25 ;;^UTILITY(U,$J,358.3,15235,2)
+26 ;;=^5007052
+27 ;;^UTILITY(U,$J,358.3,15236,0)
+28 ;;=I09.89^^56^643^17
+29 ;;^UTILITY(U,$J,358.3,15236,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,15236,1,3,0)
+32 ;;=3^Rheumatic Heart Diseases NEC
+33 ;;^UTILITY(U,$J,358.3,15236,1,4,0)
+34 ;;=4^I09.89
+35 ;;^UTILITY(U,$J,358.3,15236,2)
+36 ;;=^5007060
+37 ;;^UTILITY(U,$J,358.3,15237,0)
+38 ;;=I47.1^^56^643^24
+39 ;;^UTILITY(U,$J,358.3,15237,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,15237,1,3,0)
+42 ;;=3^Supraventricular Tachycardia
+43 ;;^UTILITY(U,$J,358.3,15237,1,4,0)
+44 ;;=4^I47.1
+45 ;;^UTILITY(U,$J,358.3,15237,2)
+46 ;;=^5007223
+47 ;;^UTILITY(U,$J,358.3,15238,0)
+48 ;;=I48.0^^56^643^15
+49 ;;^UTILITY(U,$J,358.3,15238,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,15238,1,3,0)
+52 ;;=3^Paroxysmal Atrial Fibrillation
+53 ;;^UTILITY(U,$J,358.3,15238,1,4,0)
+54 ;;=4^I48.0
+55 ;;^UTILITY(U,$J,358.3,15238,2)
+56 ;;=^90473
+57 ;;^UTILITY(U,$J,358.3,15239,0)
+58 ;;=I49.5^^56^643^23
+59 ;;^UTILITY(U,$J,358.3,15239,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,15239,1,3,0)
+62 ;;=3^Sick Sinus Syndrome
+63 ;;^UTILITY(U,$J,358.3,15239,1,4,0)
+64 ;;=4^I49.5
+65 ;;^UTILITY(U,$J,358.3,15239,2)
+66 ;;=^110404
+67 ;;^UTILITY(U,$J,358.3,15240,0)
+68 ;;=I49.8^^56^643^3
+69 ;;^UTILITY(U,$J,358.3,15240,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,15240,1,3,0)
+72 ;;=3^Cardiac Arrhythmias
+73 ;;^UTILITY(U,$J,358.3,15240,1,4,0)
+74 ;;=4^I49.8
+75 ;;^UTILITY(U,$J,358.3,15240,2)
+76 ;;=^5007236
+77 ;;^UTILITY(U,$J,358.3,15241,0)
+78 ;;=I49.9^^56^643^2
+79 ;;^UTILITY(U,$J,358.3,15241,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,15241,1,3,0)
+82 ;;=3^Cardiac Arrhythmia,Unspec
+83 ;;^UTILITY(U,$J,358.3,15241,1,4,0)
+84 ;;=4^I49.9
+85 ;;^UTILITY(U,$J,358.3,15241,2)
+86 ;;=^5007237
+87 ;;^UTILITY(U,$J,358.3,15242,0)
+88 ;;=R00.1^^56^643^1
+89 ;;^UTILITY(U,$J,358.3,15242,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,15242,1,3,0)
+92 ;;=3^Bradycardia,Unspec
+93 ;;^UTILITY(U,$J,358.3,15242,1,4,0)
+94 ;;=4^R00.1
+95 ;;^UTILITY(U,$J,358.3,15242,2)
+96 ;;=^5019164
+97 ;;^UTILITY(U,$J,358.3,15243,0)
+98 ;;=I34.1^^56^643^14
+99 ;;^UTILITY(U,$J,358.3,15243,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,15243,1,3,0)
+102 ;;=3^Nonrheumatic Mitral Valve Prolapse
+103 ;;^UTILITY(U,$J,358.3,15243,1,4,0)
+104 ;;=4^I34.1
+105 ;;^UTILITY(U,$J,358.3,15243,2)
+106 ;;=^5007170
+107 ;;^UTILITY(U,$J,358.3,15244,0)
+108 ;;=D68.4^^56^644^1
+109 ;;^UTILITY(U,$J,358.3,15244,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,15244,1,3,0)
+112 ;;=3^Acquired Coagulation Factor Deficiency
+113 ;;^UTILITY(U,$J,358.3,15244,1,4,0)
+114 ;;=4^D68.4
+115 ;;^UTILITY(U,$J,358.3,15244,2)
+116 ;;=^2235
+117 ;;^UTILITY(U,$J,358.3,15245,0)
+118 ;;=D59.9^^56^644^2
+119 ;;^UTILITY(U,$J,358.3,15245,1,0)
+120 ;;=^358.31IA^4^2
+121 ;;^UTILITY(U,$J,358.3,15245,1,3,0)
+122 ;;=3^Acquired Hemolytic Anemia,Unspec
+123 ;;^UTILITY(U,$J,358.3,15245,1,4,0)
+124 ;;=4^D59.9
+125 ;;^UTILITY(U,$J,358.3,15245,2)
+126 ;;=^5002330
+127 ;;^UTILITY(U,$J,358.3,15246,0)
+128 ;;=C91.00^^56^644^5
+129 ;;^UTILITY(U,$J,358.3,15246,1,0)
+130 ;;=^358.31IA^4^2
+131 ;;^UTILITY(U,$J,358.3,15246,1,3,0)
+132 ;;=3^Acute Lymphoblastic Leukemia,Not in Remission
+133 ;;^UTILITY(U,$J,358.3,15246,1,4,0)
+134 ;;=4^C91.00
+135 ;;^UTILITY(U,$J,358.3,15246,2)
+136 ;;=^5001762
+137 ;;^UTILITY(U,$J,358.3,15247,0)
+138 ;;=C91.01^^56^644^4
+139 ;;^UTILITY(U,$J,358.3,15247,1,0)
+140 ;;=^358.31IA^4^2
+141 ;;^UTILITY(U,$J,358.3,15247,1,3,0)
+142 ;;=3^Acute Lymphoblastic Leukemia,In Remission
+143 ;;^UTILITY(U,$J,358.3,15247,1,4,0)
+144 ;;=4^C91.01
+145 ;;^UTILITY(U,$J,358.3,15247,2)
+146 ;;=^5001763
+147 ;;^UTILITY(U,$J,358.3,15248,0)
+148 ;;=C92.01^^56^644^7
+149 ;;^UTILITY(U,$J,358.3,15248,1,0)
+150 ;;=^358.31IA^4^2
+151 ;;^UTILITY(U,$J,358.3,15248,1,3,0)
+152 ;;=3^Acute Myeloblastic Leukemia,In Remission
+153 ;;^UTILITY(U,$J,358.3,15248,1,4,0)
+154 ;;=4^C92.01
+155 ;;^UTILITY(U,$J,358.3,15248,2)
+156 ;;=^5001790
+157 ;;^UTILITY(U,$J,358.3,15249,0)
+158 ;;=C92.00^^56^644^8
+159 ;;^UTILITY(U,$J,358.3,15249,1,0)
+160 ;;=^358.31IA^4^2
+161 ;;^UTILITY(U,$J,358.3,15249,1,3,0)
+162 ;;=3^Acute Myeloblastic Leukemia,Not in Remission
+163 ;;^UTILITY(U,$J,358.3,15249,1,4,0)
+164 ;;=4^C92.00
+165 ;;^UTILITY(U,$J,358.3,15249,2)
+166 ;;=^5001789
+167 ;;^UTILITY(U,$J,358.3,15250,0)
+168 ;;=C92.61^^56^644^9
+169 ;;^UTILITY(U,$J,358.3,15250,1,0)
+170 ;;=^358.31IA^4^2
+171 ;;^UTILITY(U,$J,358.3,15250,1,3,0)
+172 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,In Remission
+173 ;;^UTILITY(U,$J,358.3,15250,1,4,0)
+174 ;;=4^C92.61
+175 ;;^UTILITY(U,$J,358.3,15250,2)
+176 ;;=^5001808
+177 ;;^UTILITY(U,$J,358.3,15251,0)
+178 ;;=C92.60^^56^644^10
+179 ;;^UTILITY(U,$J,358.3,15251,1,0)
+180 ;;=^358.31IA^4^2
+181 ;;^UTILITY(U,$J,358.3,15251,1,3,0)
+182 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
+183 ;;^UTILITY(U,$J,358.3,15251,1,4,0)
+184 ;;=4^C92.60
+185 ;;^UTILITY(U,$J,358.3,15251,2)
+186 ;;=^5001807
+187 ;;^UTILITY(U,$J,358.3,15252,0)
+188 ;;=C92.A1^^56^644^11
+189 ;;^UTILITY(U,$J,358.3,15252,1,0)
+190 ;;=^358.31IA^4^2
+191 ;;^UTILITY(U,$J,358.3,15252,1,3,0)
+192 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
+193 ;;^UTILITY(U,$J,358.3,15252,1,4,0)
+194 ;;=4^C92.A1
+195 ;;^UTILITY(U,$J,358.3,15252,2)
+196 ;;=^5001814
+197 ;;^UTILITY(U,$J,358.3,15253,0)
+198 ;;=C92.A0^^56^644^12
+199 ;;^UTILITY(U,$J,358.3,15253,1,0)
+200 ;;=^358.31IA^4^2
+201 ;;^UTILITY(U,$J,358.3,15253,1,3,0)
+202 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
+203 ;;^UTILITY(U,$J,358.3,15253,1,4,0)
+204 ;;=4^C92.A0
+205 ;;^UTILITY(U,$J,358.3,15253,2)
+206 ;;=^5001813
+207 ;;^UTILITY(U,$J,358.3,15254,0)
+208 ;;=C92.51^^56^644^13
+209 ;;^UTILITY(U,$J,358.3,15254,1,0)
+210 ;;=^358.31IA^4^2
+211 ;;^UTILITY(U,$J,358.3,15254,1,3,0)
+212 ;;=3^Acute Myelomonocytic Leukemia,In Remission
+213 ;;^UTILITY(U,$J,358.3,15254,1,4,0)
+214 ;;=4^C92.51
+215 ;;^UTILITY(U,$J,358.3,15254,2)
+216 ;;=^5001805
+217 ;;^UTILITY(U,$J,358.3,15255,0)
+218 ;;=C92.50^^56^644^14
+219 ;;^UTILITY(U,$J,358.3,15255,1,0)
+220 ;;=^358.31IA^4^2
+221 ;;^UTILITY(U,$J,358.3,15255,1,3,0)
+222 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
+223 ;;^UTILITY(U,$J,358.3,15255,1,4,0)
+224 ;;=4^C92.50
+225 ;;^UTILITY(U,$J,358.3,15255,2)
+226 ;;=^5001804
+227 ;;^UTILITY(U,$J,358.3,15256,0)
+228 ;;=C94.40^^56^644^17
+229 ;;^UTILITY(U,$J,358.3,15256,1,0)
+230 ;;=^358.31IA^4^2
+231 ;;^UTILITY(U,$J,358.3,15256,1,3,0)
+232 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
+233 ;;^UTILITY(U,$J,358.3,15256,1,4,0)
+234 ;;=4^C94.40
+235 ;;^UTILITY(U,$J,358.3,15256,2)
+236 ;;=^5001843
+237 ;;^UTILITY(U,$J,358.3,15257,0)
+238 ;;=C94.42^^56^644^15
+239 ;;^UTILITY(U,$J,358.3,15257,1,0)
+240 ;;=^358.31IA^4^2
+241 ;;^UTILITY(U,$J,358.3,15257,1,3,0)
+242 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
+243 ;;^UTILITY(U,$J,358.3,15257,1,4,0)
+244 ;;=4^C94.42
+245 ;;^UTILITY(U,$J,358.3,15257,2)
+246 ;;=^5001845
+247 ;;^UTILITY(U,$J,358.3,15258,0)
+248 ;;=C94.41^^56^644^16
+249 ;;^UTILITY(U,$J,358.3,15258,1,0)
+250 ;;=^358.31IA^4^2
+251 ;;^UTILITY(U,$J,358.3,15258,1,3,0)
+252 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
+253 ;;^UTILITY(U,$J,358.3,15258,1,4,0)
+254 ;;=4^C94.41
+255 ;;^UTILITY(U,$J,358.3,15258,2)
+256 ;;=^5001844
+257 ;;^UTILITY(U,$J,358.3,15259,0)
+258 ;;=D62.^^56^644^18
+259 ;;^UTILITY(U,$J,358.3,15259,1,0)
+260 ;;=^358.31IA^4^2
+261 ;;^UTILITY(U,$J,358.3,15259,1,3,0)
+262 ;;=3^Acute Posthemorrhagic Anemia
+263 ;;^UTILITY(U,$J,358.3,15259,1,4,0)
+264 ;;=4^D62.
+265 ;;^UTILITY(U,$J,358.3,15259,2)
+266 ;;=^267986
+267 ;;^UTILITY(U,$J,358.3,15260,0)
+268 ;;=C92.41^^56^644^19
+269 ;;^UTILITY(U,$J,358.3,15260,1,0)
+270 ;;=^358.31IA^4^2
+271 ;;^UTILITY(U,$J,358.3,15260,1,3,0)
+272 ;;=3^Acute Promyelocytic Leukemia,In Remission
+273 ;;^UTILITY(U,$J,358.3,15260,1,4,0)
+274 ;;=4^C92.41
+275 ;;^UTILITY(U,$J,358.3,15260,2)
+276 ;;=^5001802
+277 ;;^UTILITY(U,$J,358.3,15261,0)
+278 ;;=C92.40^^56^644^20
+279 ;;^UTILITY(U,$J,358.3,15261,1,0)
+280 ;;=^358.31IA^4^2
+281 ;;^UTILITY(U,$J,358.3,15261,1,3,0)
+282 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
+283 ;;^UTILITY(U,$J,358.3,15261,1,4,0)
+284 ;;=4^C92.40
+285 ;;^UTILITY(U,$J,358.3,15261,2)
+286 ;;=^5001801
+287 ;;^UTILITY(U,$J,358.3,15262,0)
+288 ;;=D56.0^^56^644^21
+289 ;;^UTILITY(U,$J,358.3,15262,1,0)
+290 ;;=^358.31IA^4^2
+291 ;;^UTILITY(U,$J,358.3,15262,1,3,0)
+292 ;;=3^Alpha Thalassemia
+293 ;;^UTILITY(U,$J,358.3,15262,1,4,0)
+294 ;;=4^D56.0
+295 ;;^UTILITY(U,$J,358.3,15262,2)
+296 ;;=^340494
+297 ;;^UTILITY(U,$J,358.3,15263,0)
+298 ;;=D63.1^^56^644^23
+299 ;;^UTILITY(U,$J,358.3,15263,1,0)
+300 ;;=^358.31IA^4^2
+301 ;;^UTILITY(U,$J,358.3,15263,1,3,0)
+302 ;;=3^Anemia in Chronic Kidney Disease
+303 ;;^UTILITY(U,$J,358.3,15263,1,4,0)
+304 ;;=4^D63.1
+305 ;;^UTILITY(U,$J,358.3,15263,2)
+306 ;;=^332908
+307 ;;^UTILITY(U,$J,358.3,15264,0)
+308 ;;=D63.0^^56^644^24
+309 ;;^UTILITY(U,$J,358.3,15264,1,0)
+310 ;;=^358.31IA^4^2
+311 ;;^UTILITY(U,$J,358.3,15264,1,3,0)
+312 ;;=3^Anemia in Neoplastic Disease
+313 ;;^UTILITY(U,$J,358.3,15264,1,4,0)
+314 ;;=4^D63.0
+315 ;;^UTILITY(U,$J,358.3,15264,2)
+316 ;;=^321978
+317 ;;^UTILITY(U,$J,358.3,15265,0)
+318 ;;=D63.8^^56^644^22
+319 ;;^UTILITY(U,$J,358.3,15265,1,0)
+320 ;;=^358.31IA^4^2
+321 ;;^UTILITY(U,$J,358.3,15265,1,3,0)
+322 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
+323 ;;^UTILITY(U,$J,358.3,15265,1,4,0)
+324 ;;=4^D63.8
+325 ;;^UTILITY(U,$J,358.3,15265,2)
+326 ;;=^5002343
+327 ;;^UTILITY(U,$J,358.3,15266,0)
+328 ;;=C22.3^^56^644^27
+329 ;;^UTILITY(U,$J,358.3,15266,1,0)
+330 ;;=^358.31IA^4^2
+331 ;;^UTILITY(U,$J,358.3,15266,1,3,0)
+332 ;;=3^Angiosarcoma of Liver
+333 ;;^UTILITY(U,$J,358.3,15266,1,4,0)
+334 ;;=4^C22.3
+335 ;;^UTILITY(U,$J,358.3,15266,2)
+336 ;;=^5000936
+337 ;;^UTILITY(U,$J,358.3,15267,0)
+338 ;;=D61.9^^56^644^28
+339 ;;^UTILITY(U,$J,358.3,15267,1,0)
+340 ;;=^358.31IA^4^2
+341 ;;^UTILITY(U,$J,358.3,15267,1,3,0)
+342 ;;=3^Aplastic Anemia,Unspec
+343 ;;^UTILITY(U,$J,358.3,15267,1,4,0)
+344 ;;=4^D61.9
+345 ;;^UTILITY(U,$J,358.3,15267,2)
+346 ;;=^5002342
+347 ;;^UTILITY(U,$J,358.3,15268,0)
+348 ;;=D56.1^^56^644^34
+349 ;;^UTILITY(U,$J,358.3,15268,1,0)
+350 ;;=^358.31IA^4^2
+351 ;;^UTILITY(U,$J,358.3,15268,1,3,0)
+352 ;;=3^Beta Thalassemia
+353 ;;^UTILITY(U,$J,358.3,15268,1,4,0)
+354 ;;=4^D56.1
+355 ;;^UTILITY(U,$J,358.3,15268,2)
+356 ;;=^340495
+357 ;;^UTILITY(U,$J,358.3,15269,0)
+358 ;;=C83.79^^56^644^36
+359 ;;^UTILITY(U,$J,358.3,15269,1,0)
+360 ;;=^358.31IA^4^2
+361 ;;^UTILITY(U,$J,358.3,15269,1,3,0)
+362 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
+363 ;;^UTILITY(U,$J,358.3,15269,1,4,0)
+364 ;;=4^C83.79
+365 ;;^UTILITY(U,$J,358.3,15269,2)
+366 ;;=^5001600
+367 ;;^UTILITY(U,$J,358.3,15270,0)
+368 ;;=C83.70^^56^644^37
+369 ;;^UTILITY(U,$J,358.3,15270,1,0)
+370 ;;=^358.31IA^4^2
+371 ;;^UTILITY(U,$J,358.3,15270,1,3,0)
+372 ;;=3^Burkitt Lymphoma,Unspec Site
+373 ;;^UTILITY(U,$J,358.3,15270,1,4,0)
+374 ;;=4^C83.70
+375 ;;^UTILITY(U,$J,358.3,15270,2)
+376 ;;=^5001591
+377 ;;^UTILITY(U,$J,358.3,15271,0)
+378 ;;=D09.0^^56^644^44
+379 ;;^UTILITY(U,$J,358.3,15271,1,0)
+380 ;;=^358.31IA^4^2
+381 ;;^UTILITY(U,$J,358.3,15271,1,3,0)
+382 ;;=3^Carcinoma in Situ of Bladder
+383 ;;^UTILITY(U,$J,358.3,15271,1,4,0)
+384 ;;=4^D09.0
+385 ;;^UTILITY(U,$J,358.3,15271,2)
+386 ;;=^267742
+387 ;;^UTILITY(U,$J,358.3,15272,0)
+388 ;;=D06.9^^56^644^45
+389 ;;^UTILITY(U,$J,358.3,15272,1,0)
+390 ;;=^358.31IA^4^2
+391 ;;^UTILITY(U,$J,358.3,15272,1,3,0)
+392 ;;=3^Carcinoma in Situ of Cervix
+393 ;;^UTILITY(U,$J,358.3,15272,1,4,0)
+394 ;;=4^D06.9
+395 ;;^UTILITY(U,$J,358.3,15272,2)
+396 ;;=^5001941
+397 ;;^UTILITY(U,$J,358.3,15273,0)
+398 ;;=D06.0^^56^644^47
+399 ;;^UTILITY(U,$J,358.3,15273,1,0)
+400 ;;=^358.31IA^4^2
+401 ;;^UTILITY(U,$J,358.3,15273,1,3,0)
+402 ;;=3^Carcinoma in Situ of Endocervix
+403 ;;^UTILITY(U,$J,358.3,15273,1,4,0)
+404 ;;=4^D06.0
+405 ;;^UTILITY(U,$J,358.3,15273,2)
+406 ;;=^5001938
+407 ;;^UTILITY(U,$J,358.3,15274,0)
+408 ;;=D06.1^^56^644^48
+409 ;;^UTILITY(U,$J,358.3,15274,1,0)
+410 ;;=^358.31IA^4^2
+411 ;;^UTILITY(U,$J,358.3,15274,1,3,0)
+412 ;;=3^Carcinoma in Situ of Exocervix
+413 ;;^UTILITY(U,$J,358.3,15274,1,4,0)
+414 ;;=4^D06.1
+415 ;;^UTILITY(U,$J,358.3,15274,2)
+416 ;;=^5001939
+417 ;;^UTILITY(U,$J,358.3,15275,0)
+418 ;;=D06.7^^56^644^46
+419 ;;^UTILITY(U,$J,358.3,15275,1,0)
+420 ;;=^358.31IA^4^2
+421 ;;^UTILITY(U,$J,358.3,15275,1,3,0)
+422 ;;=3^Carcinoma in Situ of Cervix,Other Parts
+423 ;;^UTILITY(U,$J,358.3,15275,1,4,0)
+424 ;;=4^D06.7
+425 ;;^UTILITY(U,$J,358.3,15275,2)
+426 ;;=^5001940
+427 ;;^UTILITY(U,$J,358.3,15276,0)
+428 ;;=D04.9^^56^644^49
+429 ;;^UTILITY(U,$J,358.3,15276,1,0)
+430 ;;=^358.31IA^4^2
+431 ;;^UTILITY(U,$J,358.3,15276,1,3,0)
+432 ;;=3^Carcinoma in Situ of Skin
+433 ;;^UTILITY(U,$J,358.3,15276,1,4,0)
+434 ;;=4^D04.9
+435 ;;^UTILITY(U,$J,358.3,15276,2)
+436 ;;=^5001925
+437 ;;^UTILITY(U,$J,358.3,15277,0)
+438 ;;=C91.11^^56^644^52
+439 ;;^UTILITY(U,$J,358.3,15277,1,0)
+440 ;;=^358.31IA^4^2
+441 ;;^UTILITY(U,$J,358.3,15277,1,3,0)
+442 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
+443 ;;^UTILITY(U,$J,358.3,15277,1,4,0)
+444 ;;=4^C91.11
+445 ;;^UTILITY(U,$J,358.3,15277,2)
+446 ;;=^5001766
+447 ;;^UTILITY(U,$J,358.3,15278,0)
+448 ;;=C91.10^^56^644^53
+449 ;;^UTILITY(U,$J,358.3,15278,1,0)
+450 ;;=^358.31IA^4^2
+451 ;;^UTILITY(U,$J,358.3,15278,1,3,0)
+452 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
+453 ;;^UTILITY(U,$J,358.3,15278,1,4,0)
+454 ;;=4^C91.10
+455 ;;^UTILITY(U,$J,358.3,15278,2)
+456 ;;=^5001765
+457 ;;^UTILITY(U,$J,358.3,15279,0)
+458 ;;=C92.11^^56^644^54
+459 ;;^UTILITY(U,$J,358.3,15279,1,0)
+460 ;;=^358.31IA^4^2
+461 ;;^UTILITY(U,$J,358.3,15279,1,3,0)
+462 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
+463 ;;^UTILITY(U,$J,358.3,15279,1,4,0)
+464 ;;=4^C92.11
+465 ;;^UTILITY(U,$J,358.3,15279,2)
+466 ;;=^5001793
+467 ;;^UTILITY(U,$J,358.3,15280,0)
+468 ;;=C92.10^^56^644^55
+469 ;;^UTILITY(U,$J,358.3,15280,1,0)
+470 ;;=^358.31IA^4^2
+471 ;;^UTILITY(U,$J,358.3,15280,1,3,0)
+472 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
+473 ;;^UTILITY(U,$J,358.3,15280,1,4,0)
+474 ;;=4^C92.10
+475 ;;^UTILITY(U,$J,358.3,15280,2)
+476 ;;=^5001792
+477 ;;^UTILITY(U,$J,358.3,15281,0)
+478 ;;=D47.1^^56^644^56
+479 ;;^UTILITY(U,$J,358.3,15281,1,0)
+480 ;;=^358.31IA^4^2
+481 ;;^UTILITY(U,$J,358.3,15281,1,3,0)
+482 ;;=3^Chronic Myeloproliferative Disease
+483 ;;^UTILITY(U,$J,358.3,15281,1,4,0)
+484 ;;=4^D47.1
+485 ;;^UTILITY(U,$J,358.3,15281,2)
+486 ;;=^5002256
+487 ;;^UTILITY(U,$J,358.3,15282,0)
+488 ;;=C82.69^^56^644^57
+489 ;;^UTILITY(U,$J,358.3,15282,1,0)
+490 ;;=^358.31IA^4^2
+491 ;;^UTILITY(U,$J,358.3,15282,1,3,0)
+492 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
+493 ;;^UTILITY(U,$J,358.3,15282,1,4,0)
+494 ;;=4^C82.69
+495 ;;^UTILITY(U,$J,358.3,15282,2)
+496 ;;=^5001530
+497 ;;^UTILITY(U,$J,358.3,15283,0)
+498 ;;=C82.60^^56^644^58
+499 ;;^UTILITY(U,$J,358.3,15283,1,0)
+500 ;;=^358.31IA^4^2
+501 ;;^UTILITY(U,$J,358.3,15283,1,3,0)
+502 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
+503 ;;^UTILITY(U,$J,358.3,15283,1,4,0)
+504 ;;=4^C82.60
+505 ;;^UTILITY(U,$J,358.3,15283,2)
+506 ;;=^5001521
+507 ;;^UTILITY(U,$J,358.3,15284,0)
+508 ;;=D56.2^^56^644^59
+509 ;;^UTILITY(U,$J,358.3,15284,1,0)
+510 ;;=^358.31IA^4^2
+511 ;;^UTILITY(U,$J,358.3,15284,1,3,0)
+512 ;;=3^Delta-Beta Thalassemia
+513 ;;^UTILITY(U,$J,358.3,15284,1,4,0)
+514 ;;=4^D56.2
+515 ;;^UTILITY(U,$J,358.3,15284,2)
+516 ;;=^340496
+517 ;;^UTILITY(U,$J,358.3,15285,0)
+518 ;;=D75.9^^56^644^60
+519 ;;^UTILITY(U,$J,358.3,15285,1,0)
+520 ;;=^358.31IA^4^2
+521 ;;^UTILITY(U,$J,358.3,15285,1,3,0)
+522 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
+523 ;;^UTILITY(U,$J,358.3,15285,1,4,0)
+524 ;;=4^D75.9
+525 ;;^UTILITY(U,$J,358.3,15285,2)
+526 ;;=^5002393
+527 ;;^UTILITY(U,$J,358.3,15286,0)
+528 ;;=D59.0^^56^644^63
+529 ;;^UTILITY(U,$J,358.3,15286,1,0)
+530 ;;=^358.31IA^4^2
+531 ;;^UTILITY(U,$J,358.3,15286,1,3,0)
+532 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
+533 ;;^UTILITY(U,$J,358.3,15286,1,4,0)
+534 ;;=4^D59.0
+535 ;;^UTILITY(U,$J,358.3,15286,2)
+536 ;;=^5002323
+537 ;;^UTILITY(U,$J,358.3,15287,0)
+538 ;;=D59.2^^56^644^64
+539 ;;^UTILITY(U,$J,358.3,15287,1,0)
+540 ;;=^358.31IA^4^2
+541 ;;^UTILITY(U,$J,358.3,15287,1,3,0)
+542 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
+543 ;;^UTILITY(U,$J,358.3,15287,1,4,0)
+544 ;;=4^D59.2
+545 ;;^UTILITY(U,$J,358.3,15287,2)
+546 ;;=^5002325
+547 ;;^UTILITY(U,$J,358.3,15288,0)
+548 ;;=R59.9^^56^644^67
+549 ;;^UTILITY(U,$J,358.3,15288,1,0)
+550 ;;=^358.31IA^4^2
+551 ;;^UTILITY(U,$J,358.3,15288,1,3,0)
+552 ;;=3^Enlarged Lymph Nodes,Unspec
+553 ;;^UTILITY(U,$J,358.3,15288,1,4,0)
+554 ;;=4^R59.9
+555 ;;^UTILITY(U,$J,358.3,15288,2)
+556 ;;=^5019531
+557 ;;^UTILITY(U,$J,358.3,15289,0)
+558 ;;=D47.3^^56^644^68
+559 ;;^UTILITY(U,$J,358.3,15289,1,0)
+560 ;;=^358.31IA^4^2
+561 ;;^UTILITY(U,$J,358.3,15289,1,3,0)
+562 ;;=3^Essential Thrombocythemia
+563 ;;^UTILITY(U,$J,358.3,15289,1,4,0)
+564 ;;=4^D47.3
+565 ;;^UTILITY(U,$J,358.3,15289,2)
+566 ;;=^5002258
+567 ;;^UTILITY(U,$J,358.3,15290,0)
+568 ;;=C82.09^^56^644^69
+569 ;;^UTILITY(U,$J,358.3,15290,1,0)
+570 ;;=^358.31IA^4^2
+571 ;;^UTILITY(U,$J,358.3,15290,1,3,0)
+572 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
+573 ;;^UTILITY(U,$J,358.3,15290,1,4,0)
+574 ;;=4^C82.09
+575 ;;^UTILITY(U,$J,358.3,15290,2)
+576 ;;=^5001470
+577 ;;^UTILITY(U,$J,358.3,15291,0)
+578 ;;=C82.00^^56^644^70
+579 ;;^UTILITY(U,$J,358.3,15291,1,0)
+580 ;;=^358.31IA^4^2
+581 ;;^UTILITY(U,$J,358.3,15291,1,3,0)
+582 ;;=3^Follicular Lymphoma Grade I,Unspec Site
+583 ;;^UTILITY(U,$J,358.3,15291,1,4,0)
+584 ;;=4^C82.00
+585 ;;^UTILITY(U,$J,358.3,15291,2)
+586 ;;=^5001461
+587 ;;^UTILITY(U,$J,358.3,15292,0)
+588 ;;=C82.19^^56^644^71
+589 ;;^UTILITY(U,$J,358.3,15292,1,0)
+590 ;;=^358.31IA^4^2
+591 ;;^UTILITY(U,$J,358.3,15292,1,3,0)
+592 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
+593 ;;^UTILITY(U,$J,358.3,15292,1,4,0)
+594 ;;=4^C82.19
+595 ;;^UTILITY(U,$J,358.3,15292,2)
+596 ;;=^5001480
+597 ;;^UTILITY(U,$J,358.3,15293,0)
+598 ;;=C82.10^^56^644^72
+599 ;;^UTILITY(U,$J,358.3,15293,1,0)
+600 ;;=^358.31IA^4^2
+601 ;;^UTILITY(U,$J,358.3,15293,1,3,0)
+602 ;;=3^Follicular Lymphoma Grade II,Unspec Site
+603 ;;^UTILITY(U,$J,358.3,15293,1,4,0)
+604 ;;=4^C82.10
+605 ;;^UTILITY(U,$J,358.3,15293,2)
+606 ;;=^5001471
+607 ;;^UTILITY(U,$J,358.3,15294,0)
+608 ;;=C82.29^^56^644^73
+609 ;;^UTILITY(U,$J,358.3,15294,1,0)
+610 ;;=^358.31IA^4^2
+611 ;;^UTILITY(U,$J,358.3,15294,1,3,0)
+612 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
+613 ;;^UTILITY(U,$J,358.3,15294,1,4,0)
+614 ;;=4^C82.29
+615 ;;^UTILITY(U,$J,358.3,15294,2)
+616 ;;=^5001490
+617 ;;^UTILITY(U,$J,358.3,15295,0)
+618 ;;=C82.20^^56^644^74
+619 ;;^UTILITY(U,$J,358.3,15295,1,0)
+620 ;;=^358.31IA^4^2
+621 ;;^UTILITY(U,$J,358.3,15295,1,3,0)
+622 ;;=3^Follicular Lymphoma Grade III,Unspec Site
+623 ;;^UTILITY(U,$J,358.3,15295,1,4,0)
+624 ;;=4^C82.20
+625 ;;^UTILITY(U,$J,358.3,15295,2)
+626 ;;=^5001481
+627 ;;^UTILITY(U,$J,358.3,15296,0)
+628 ;;=C82.39^^56^644^75
+629 ;;^UTILITY(U,$J,358.3,15296,1,0)
+630 ;;=^358.31IA^4^2
+631 ;;^UTILITY(U,$J,358.3,15296,1,3,0)
+632 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
+633 ;;^UTILITY(U,$J,358.3,15296,1,4,0)
+634 ;;=4^C82.39
+635 ;;^UTILITY(U,$J,358.3,15296,2)
+636 ;;=^5001500
+637 ;;^UTILITY(U,$J,358.3,15297,0)
+638 ;;=C82.30^^56^644^76
+639 ;;^UTILITY(U,$J,358.3,15297,1,0)
+640 ;;=^358.31IA^4^2
+641 ;;^UTILITY(U,$J,358.3,15297,1,3,0)
+642 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
+643 ;;^UTILITY(U,$J,358.3,15297,1,4,0)
+644 ;;=4^C82.30
+645 ;;^UTILITY(U,$J,358.3,15297,2)
+646 ;;=^5001491
+647 ;;^UTILITY(U,$J,358.3,15298,0)
+648 ;;=C82.49^^56^644^77
+649 ;;^UTILITY(U,$J,358.3,15298,1,0)
+650 ;;=^358.31IA^4^2
+651 ;;^UTILITY(U,$J,358.3,15298,1,3,0)
+652 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
+653 ;;^UTILITY(U,$J,358.3,15298,1,4,0)
+654 ;;=4^C82.49
+655 ;;^UTILITY(U,$J,358.3,15298,2)
+656 ;;=^5001510
+657 ;;^UTILITY(U,$J,358.3,15299,0)
+658 ;;=C82.40^^56^644^78
+659 ;;^UTILITY(U,$J,358.3,15299,1,0)
+660 ;;=^358.31IA^4^2
+661 ;;^UTILITY(U,$J,358.3,15299,1,3,0)
+662 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
+663 ;;^UTILITY(U,$J,358.3,15299,1,4,0)
+664 ;;=4^C82.40
+665 ;;^UTILITY(U,$J,358.3,15299,2)
+666 ;;=^5001501
+667 ;;^UTILITY(U,$J,358.3,15300,0)
+668 ;;=C82.99^^56^644^79
+669 ;;^UTILITY(U,$J,358.3,15300,1,0)
+670 ;;=^358.31IA^4^2
